Alliance Global Partners reissued their buy rating on ... The company’s lead product is IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer ...

IGC Pharma Announces Equity Analyst Update by Alliance Global Partners (AGP ... an expansion of its clinical research program for IGC-AD1, an investigational treatment for Alzheimer's disease.

Long-Term Safety of Ruxolitinib Cream in Adults and Adolescents with Mild-to-Moderate Atopic Dermatitis: Adverse Events of Interest from the TRuE-AD1 and TRuE-AD2 Phase ... About Incyte A global ...

Two posters presented at the 2025 American Academy of Dermatology Annual Meeting reaffirmed the impact of ruxolitinib cream ...

‘Half of us here are dual citizens, including me — Canadian and American, half of us,’ Point Roberts resident Brian Calder told Global News. Watch the online edition of Global News Hour at 6 B ...

billboard global 200 the week's most popular songs based on streaming and sales activity from over 200 territories around the world — including the united states — as tracked by luminate. the ...

billboard global excl. us the week's most popular songs based on streaming and sales activity from over 200 territories around the world — excluding the united states — as tracked by luminate ...

UniCredit S.p.A. €51.95 1.55 3.08% ...

As of 3:08:43 PM EDT. Market Open. Loading Chart for IGC ...

Traders work on the floor at the New York Stock Exchange (NYSE) in New York City, U.S., February 12, 2025. REUTERS/Brendan McDermid/File photo ...